Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Supplementary Methods from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

View through CrossRef
Supplementary Methods from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC
Title: Supplementary Methods from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC
Description:
Supplementary Methods from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC.

Related Results

Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
PB1950 GENERIC IMATINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA‐ CLINICAL EXPERIENCE OVER A SIX YEAR PERIOD
PB1950 GENERIC IMATINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA‐ CLINICAL EXPERIENCE OVER A SIX YEAR PERIOD
Background:Upon the introduction of the first tyrosine kinase inhibitor (TKI), imatinib, the treatment of chronic myeloid leukaemia has radically changed. The very high treatment c...
Abstract 795: Dovitinib exerts potent antitumor effects in gastrointestinal stromal tumors
Abstract 795: Dovitinib exerts potent antitumor effects in gastrointestinal stromal tumors
Abstract Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract. Although Imatinib is the current first-l...

Back to Top